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Abstract
The ability of microalbuminuria to predict early progressive renal function decline in type-1 
diabetic patients has been questioned. To resolve this, we determined the plasma proteome 
differences between microalbuminuric patients with type-1 diabetes and stable renal function 
(controls) and patients at risk for early progressive renal function decline (cases) and asked 
whether these differences have value as surrogate biomarkers. Mass spectrometry was used to 
analyze small (less than 3 kDa) plasma peptides isolated from well-matched case and control 
plasma obtained at the beginning of an 8-12 year follow-up period. Spearman analysis of plasma 
peptide abundance and the rate of renal function decline during follow-up identified seven masses 
with a significant negative correlation with early progressive renal function decline. Tandem mass 
spectrometry identified three fragments of high molecular weight kininogen. Increased plasma 
high molecular weight kininogen in the cases was confirmed by immunoblot. One peptide, des-
Arg9-BK(1-8), induced Erk1/2 phosphorylation when added apically to two proximal tubular cell 
lines grown on permeable inserts. Thus, we have identified plasma protein fragments, some of 
which have biological activity with moderate to strong correlation, with early progressive renal 
function decline in microalbuminuric patients with type-1 diabetes. Other peptides are candidates 
for validation as candidate biomarkers of diabetes-associated renal dysfunction.
Introduction
Microalbuminuria (MA) has been considered the primary diagnostic tool to identify type 1 
diabetes mellitus (T1D) patients at risk for progressive renal dysfunction1,2. However, the 
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tcorrelation of MA with future renal dysfunction in diabetics has now been called into 
question. Several findings indicate that MA may not reliably herald the beginning of renal 
dysfunction. First, only approximately 20% of patients with MA will progress to 
proteinuria3; second, many patients with MA can revert to normoalbuminuria4-6; and third, 
many individuals with T1D have already experienced early progressive renal function 
decline (ERFD) before or coincidental with MA onset7,8. These findings have called into 
question the model of diabetic nephropathy in which MA conveyed a high risk of 
progressive renal dysfunction and support a new model in which only a subset of those with 
MA develop progressive ERFD. This change in our understanding of diabetic renal disease 
also is indicative of our incomplete understanding of the mechanisms of ERFD, a process 
that takes place while measured renal function is still in the normal or even elevated range. 
These findings emphasize the need for further studies to understand the pathophysiology of 
ERFD in patients with MA and to identify those T1D patients at risk for early renal damage.
We addressed the hypothesis that qualitative differences in plasma proteins might provide 
insight into ERFD pathophysiology and serve as candidate biomarkers of the risk of 
progressive ERFD and progressive renal function loss. To address this hypothesis we have 
analyzed plasma samples obtained during the 1st Joslin Study of the Natural History of 
Microalbuminuria in Type 1 Diabetes using LC-MALDI-TOF MS to compare the low 
molecular weight protein (less than 3,000 Daltons) or peptidomic plasma fraction. We 
analyzed the plasma peptidome of patients matched for cystatin C estimated glomerular 
filtration rate (eGFR), MA, and medications (among other clinical parameters) comparing 
those who retained stable renal function to those that developed ERFD during subsequent 
8-12 years of follow-up. We hypothesized that qualitative differences in the low molecular 
weight plasma proteome (the peptidome) might provide insight into the etiology of early 
progressive RFD and serve as putative biomarkers of future progression. We observed a 
striking correlation between the rate of future renal function decline and components of the 
kallikrein-kininogen system. These protein fragments should now be considered as 
candidates for confirmation in larger studies as candidate biomarkers of ERFD and 
predictors of renal dysfunction in T1D.
Results
Characteristics of the Study Population
The study population was comprised of the patients whose onset of MA was documented in 
the 1st Joslin Study of the Natural History of Microalbuminuria in Type 1 Diabetes. 
Additional eligibility criteria included follow-up examinations spanning at least 8-12 years 
after MA onset for estimating the rate of GFR decline and availability of a 6 ml aliquot of 
stored urine for peptide analysis9. Thirty-three patients (16 cases and 17 controls) selected 
from a previous urinary biomarker study were who met all eligibility criteria (cases with 
renal function decline defined as a decline of 3.3% or more per year (range: −3.3 to −16.1% 
per year), and controls with lesser rates of renal function decline (range: +1.9 to −3.2% per 
year) had contemporaneous plasma samples avaiable for the current study.
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To detect peptides whose abundance strictly correlated with the linear estimate of renal 
function and not simply a discrete clinical group, a Spearman rank order correlation analysis 
was performed comparing peptide abundance with the rate of renal function decline. A total 
of seven peptides were identified with Spearman correlation value ranked between an 
absolute value of −0.45 and −0.51 (p<0.001) (Table 1). As such if validated, they may have 
a value to identify patients with an increased risk of the development of ERFD.
Identification of Peptide Amino Acid Sequence by Mass Spectrometry
To better understand the possible role of the selected peptide masses in the etiology of 
ERFD we sought to identify partial amino acid sequence tagging information using tandem 
mass spectrometry. Two of the seven masses were not fragmented due to low intensity and 
proximity of the monoisotopic peak to larger more intense ions. Using the parent peptide 
mass, the peptide fragmentation data (see supplemental data for peak list information and 
fragmentation spectra) gained from the tandem MS experiments, and the data analysis 
software, Matrix Science Mascot, amino acid sequences were assigned to a total of four of 
the five peptides submitted for MS/MS analysis (Table 1). The results of these analyses 
identified fragments of two plasma proteins including kininogen-1 (three fragments) and a 
fragment of plasma kallikrein-sensitive glycoprotein (inter-alpha-trypsin inhibitor heavy 
chain H4, ITIH4). The comparison of the fragmentation spectra for synthetic peptides with 
experimental data supported these peptide assignments (see supplemental data). The kinin 
peptides were modified by C-terminal proteolysis and/or prolyl-specific hydroxylation. 
While the strength of the assignments for these peptides as candidate biomarkers for ERFD 
in T1D is based on the Spearman Correlation analysis, we provide a figure (Figure1) to 
illustrate the comparison of the means for these plasma peptide abundances. These data 
suggest that in these patients the abundances of specific plasma peptides can begin to predict 
significant declines in GFR. In general, a comparison between cases and controls for these 
peptides identified a 30-50% increased mean abundance in patients who were at risk of 
ERFD (Figure1, Table 1).
Differential Abundance of High Molecular Weight Kininogen in Plasma
We then examined whether the increased abundance of bradykinin (BK) forms in case 
plasma might result from increased amounts of its precursor kininogen. Using an antibody 
developed against recombinant high molecular weight kininogen (rhKininogen: aa 19-644), 
we analyzed by immunoblot the expression of high molecular weight kininogen within the 
plasma sample set used for the peptidomic analysis. The products of high molecular weight 
kininogen precursor is proteolysis by plasma kallikrein are BK and a high molecular weight 
kininogen α1ß1 heterodimer held together by a single disulfide chain. Because the α1 and ß1 
monomers have masses similar to albumin, we first depleted the plasma samples of albumin 
prior to immunoblot analysis. Additionally, for this comparison samples were selected from 
the patient populations with the most severe loss of renal function and most stable renal 
function. These samples were then resolved by 10% SDS-PAGE and putative kininogen 
heavy (α) and light (ß) chains were identified by immunoblot. Shown in Figure 2 are 
immunoblot data for the comparison of three cases and three control samples. Immunoblot 
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tdensitometry measurements of a total of six patient samples were used to estimate 
differential abundance of kininogen immune-positive bands. Two sets of immune-positive 
bands were detectable in plasma and by t-test were significantly (p<0.05) increased 
approximately 30-40% in case plasma.
Biological Activity of the des-Arg9-BK(1-8) Fragment in a Renal Tubular Cell Line
We wished to examine if one of the BK peptides prevalent in patients with ERFD exhibited 
biological activity in renal cells. We chose the des-Arg9-BK(1-8) peptide because it is 
reported to exhibit activity only when it binds to the bradykinin-1 receptor (B1R); whose 
expression is increased in diabetic mice 10. We examined the endpoint of ERK 
phosphorylation as it has been shown to be a downstream signaling molecule in the B1R 
pathway11. Initially, we incubated immortalized mouse proximal tubule cells grown on 
plastic with 5mM glucose, or 30 mM glucose, or 5 mM glucose + mannitol 25mM (as an 
osmotic control) in the presence and absence of 100 nM des-Arg9 BK (1-8) and observed 
des-Arg9 BK (1-8) effects in normal glucose (5 mM) or in the osmotic control to have 
comparable ERK phosphorylation to that induced by high glucose alone (30 mM) 
(supplemental figure S3a). The most substantial increase in ERK phosphorylation was seen 
when cells were exposed to des-Arg9 BK (1-8) in the presence of high glucose (30 mM). As 
epithelial cells grown on plastic may not recapitulate a true polarized phenotype, we 
repeated these experiments with the mouse proximal tubule cell line grown on permeable 
inserts and evaluated the effects on Erk1/2 phosphorylation following either apical or basilar 
delivery of the peptide. In comparison with vehicle, apical but not basilar delivery of the 
des-Arg9 BK (1-8) resulted in a statistically significant difference by ANOVA analysis in 
Erk1/2 phosphorylation with comparing 5mM glucose control samples with 30mM glucose 
treated cells or des-Arg9 BK (1-8) treated cells (Figure 3a-b). Finally, to determine if this 
observation was isolated to the mouse renal proximal tubular cell line these apical delivery 
experiments were repeated using an opossum kidney cell (OKC) proximal tubular cell line. 
While the OKC cell line did not respond robustly for induction of Erk1/2 phosphorylation 
by media alone (30mM glucose), apical treatment of the OKC in 5mM glucose, 30mM 
glucose, and 5mM glucose plus 25mM mannitol with des-Arg9 BK (1-8) induced a 
statistically significant increase in Erk1/2 phosphorylation compared to normal control 
(Figure 3c).
DISCUSSION
The goal of this study was to identify plasma proteome components associated with the risk 
of progressive ERFD, a phase of diabetic nephropathy associated with the initiation of 
progressive renal dysfunction while GFR is still in the normal range7. To achieve this goal 
we studied plasma samples obtained soon after enrollment in the 1st Joslin Study of the 
Natural History of Microalbuminuria in Type 1 Diabetes. The samples studied were well-
matched for microalbuminuria, estimated GFR and other clinical factors. These patients had 
been followed for 8 to 12 years, thereby allowing us to classify patients into groups with 
either long-term stable renal function or progressive renal function deterioration. As such, 
the samples could be used to either correlate the presence of a peptide detected in the 
enrollment plasma sample with the rate of future renal function decline or to detect peptides 
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tthat identify patients that retain stable renal function as compared to those diabetics with 
ERFDs demonstrated here. MS analysis was used to select and characterize changes in 
plasma abundance of high molecular weight kininogen derived peptides and kinin cleavage 
products. These peptides included two forms of des-Arg9-BK (1-8), des-Phe8-des-Arg9-BK 
(1-7) form, as well as a fragment of the plasma kallikrein-sensitive glycoprotein (inter-alpha 
trypsin inhibitor H4, ITIH4). The novel findings in these studies are that quantifiable 
changes in plasma low and high molecular weight protein expression occur very early in 
DN12. We examined at least one mechanism by which case samples could have increased 
expression of BK variants by measuring high molecular weight kininogen protein from 
which BK is derived. We observed increased expression of high molecular weight kininogen 
heavy chain and light chains in the plasma of cases compared controls, a finding that may 
explain the increased amount of BK available for post-translational modification.
The plasma kallikrein-kininogen system (KKS) plays a substantial role in regulation of 
coagulation and inflammation. Kallikrein is a highly abundant plasma protein that is 
activated by contact with negatively charged surfaces. When active, kallikrein cleaves one 
of its substrates, high molecular weight kininogen, resulting in release of BK. BK exerts its 
actions promoting vasodilation, vascular permeability and edema by stimulating cognate cell 
surface receptors, B1R and B2R. B2R are activated by binding of BK and are constitutively 
expressed in vascular tissues, while B1R are activated by binding of desArg9 BK(1-8) and 
their expression is induced by cellular ischemia, inflammation and in some instances 
diabetes10,12. In humans and rodents, BK is degraded C-terminally by three proteases 
including angiotensin-converting enzyme-1 (ACE1), aminopeptidase P (APP) and 
carboxypeptidase N (CPN)13,14. These enzymes convert BK to desArg9 BK (1-8), desArg1-
Pro2 BK (3-9) and desPhe8-Arg9-BK (1-7) respectively. Recently a second angiotensin-
converting enzyme (ACE2) has been identified. ACE2 is the principle route of desArg9-BK 
(1-8) degradation and as has been recently reviewed is insensitive to standard ACE 
inhibitors15.
The association of the KKS in diabetic nephropathy has been examined extensively. In 
human studies, Jaffa et al studied plasma samples from patients enrolled in the Diabetes 
Control and Complications Trial and observed that plasma pre-kallikrein levels correlated 
with hypertension, albumin excretion rates, and the development of MA16. The same group 
also demonstrated that diabetic patients with glomerular hyper-filtration had increased 
urinary excretion of active kallikrein. Animal studies of the role of the KKS product BK in 
diabetic nephropathy have produced contradictory findings. In Akita diabetic mice, B2R 
deletion exacerbated albuminuria, interstitial fibrosis and glomerulosclerosis17,18. The same 
investigators also demonstrated that B2R antagonists in several murine diabetic nephropathy 
models attenuated the beneficial effect of ACE inhibitors. In contrast, Tan et al observed an 
attenuation of diabetic nephropathy in B2R knockout mice made diabetic with 
streptozotocin19. These conflicting data may result from disparities in the animal strains or 
diabetic models used. Our data do not bring clarity to the conflicting results in these animal 
studies. However, our data do underscore the finding that the KKS system is strongly 
regulated in type -1 diabetics with ERFD.
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tOne of the goals of these studies was to discover plasma peptides that correlate with ERFD 
and that could then serve as candidate biomarkers of progressive renal dysfunction in 
MAT1D. We observed seven peptides that had a moderate to strong correlation with the rate 
of future renal function decline having Spearman correlation coefficients from −0.45 to 
−0.51. In contrast to our previous peptide biomarker studies, these seven peptides had a high 
prevalence in both case and control samples and thus are good biomarker candidates9. The 
confirmation of these prevalent peptides as biomarkers of ERFD and future renal function in 
T1D will require validation studies using large patient populations and their predictive value 
may also be strengthened by inclusion in multiple marker panels20.
In many instances, disease biomarkers are simply indicators of disease activity and are not 
reflections of disease mechanisms. However, as BK agonists have been shown to alter renal 
cell behavior21,22 we examined if one of the modified BK forms of higher abundance in 
patients with ERFD had biological activity in renal proximal tubular cells. We chose the 
des-Arg9-BK(1-8) for several reasons including a Spearman rank correlation analysis that 
showed correlation values of −0.37 in angiotensin converting enzyme inhibitor (ACEi)-
naïve patients and −0.74 in ACEi-treated patients (data not shown); suggesting patients on 
ACEi might experience greater exposure to the effects of circulating des-Arg9-BK(1-8). 
Des-Arg9-BK(1-8) is the ligand for the inducible B1R whose expression can be induced in 
diabetic proximal tubule cells. Our data demonstrated that des-Arg9-BK(1-8) stimulated 
ERK phosphorylation in a mouse proximal tubule cell line grown on plastic as well as when 
delivered apically to these cells and to second OKC proximal tubular cell line. The des-Arg9 
BK (1-8) augmented the ERK phosphorylation induced by high glucose concentrations for 
the mouse proximal tubular cell line was not observed with cells grown on permeable inserts 
and may be the results of loss of polarization or simultaneous stimulation of both apical and 
basolateral populations of B1R receptors. These data are consistent with the literature that 
B1R agonists activate ERK and indicate that at least one of the prevalent BK forms in cases 
can exhibit biological activity in the kidney. The consequences of such activity are currently 
under investigation.
In summary, we have identified peptides in the low molecular fraction of plasma that 
correlate with ERFD and progressive nephropathy in type-1 diabetes. These peptides reflect 
changes in the abundance and post-translationally modified forms of bioactive peptides. 
These differences in concentration and modification may define a new mechanism by which 
diabetic microvascular is initiated or progresses. The usefulness of these discriminating 
peptides as biomarkers of diabetes associated renal function decline should be determined in 
additional rigorous studies in a larger patient population.
Materials and Methods
Study Subjects and Plasma Sample Collection
Patients who were enrolled in the 1st Joslin Study of the Natural History of 
Microalbuminuria in Type 1 Diabetes were eligible for this pilot study7. The study protocol 
and patient consent procedures were approved by the Committee on Human Studies of the 
Joslin Diabetes Center. Urinary MA (defined as an excretion rate of 30 to 299μg/min) was 
established by repeat urine measurements during the first two years of patient follow-up. 
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evaluation were invited to provide blood samples for further study. Serial measurements of 
cystatin C were examined to determine trends in renal function changes. Cystatin C is a low 
molecular weight, cationic, non-glycosylated, protease inhibitor that is constitutively 
expressed by nucleated cells. Cystatin C has been demonstrated to perform equal to or more 
superior to serum creatinine as an estimation of glomerular filtration rates in adults with 
GFR’s greater than 60mL/min8.
Peptidomic Analysis
The low and high molecular weight plasma proteomes were separated and isolated peptides 
were analyzed as described previously9. Briefly proteins were precipitated using organic 
solvent, the soluble peptide fractions following lyophilization and quantification using a 
modified Lowery/BCA method, were separated with reversed phase (RP) capillary-high 
performance liquid chromatography, robotically spotted onto archival MALDI-TOF MS 
plates (Opti-TOF plates) and MALDI-TOF MS data acquired using an Applied Biosystems 
(Foster City, CA) AB4700 Proteomics Analyzer operating in reflectron mode. LC MALDI-
TOF MS ion chromatograms were constructed using Data Explorer software (Applied 
Biosystems) and then exported as peak list text files and used for determination of 
differential peptide abundance. Additionally, individual LC-MS spectra were concatenated 
to produce plasmapeptide LC-MALDI-TOF MS ion chromatogram per each sample 
analyzed.
Statistical Analysis of Plasma Peptide Abundance
LC-MALDI-TOF MS ion chromatograms were extracted in the form of integrated signal 
area for the peptide isotopic series (cluster area under the curve, AUC) from the 
ABI4700 .t2d files using Data Explorer (Applied Biosystems) software and exported to 
MarkerView (Applied Biosystems) software to chromatographically align and array the 
tabulated peptide peak list data using a signal-to-noise filter of 10. Three LC fractions 
collected prior to initiating the reversed phase elution gradient and following re-equilibration 
of the column from 100% solvent B to 100 solvent A were used to establish a null peptide 
mass list. These masses were subtracted from the aggregate data set.
The data were analyzed using a Spearman rank order correlation to correlate peptide 
abundance with renal function decline (estimated from -slope of linear regressions for 
annual measurements of serum cystatin C; whose individual measurements are considered 
useful for estimating the glomerular filtration rate, GFR)7,9. Prior to the calculation of the 
Spearman rank order correlation, the data were preprocessed to filter-out and eliminate the 
peptides that were detected in less than 80% of all samples. In each case of a missing 
peptide abundance value (cluster AUC), MALDI TOF MS spectra were manually reviewed 
and background signal for 1 m/z centroided around the reported mass were estimated and 
recorded. The requirement for a given peptide’s presence in 80%+ of all samples was used 
to provide for a robust peptide candidate biomarker panel. Spearman rank order correlation 
values between −1.0 and −0.45 or between +1.0 and +0.45 were considered meaningful. In 
addition abundance of peptides falling within these two ranges were compared between 
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variances.
Computer Assisted Tandem-MS Data Analysis
Candidate peptide m/z values selected from Spearman rank order correlation analyses were 
analyzed in tandem MS experiments to better understand their importance in diabetic ERFD. 
The selected peptide masses were used to establish a MALDI ion inclusion list and were 
fragmented using the AB4700 Proteomics Analyzer as previously described9. Final 
fragmentation data were collected as averaged data from 1500 laser shots. The peptide 
fragmentation information was searched against the Swiss-Prot database using Matrix 
Science Mascot software (v1.9) to identify a peptide with the highest correlative amino acid 
sequence. Criteria used for analysis were a) unconstrained proteolytic search (no enzyme 
fragmentation criteria stipulated) b) partial peptide modification of sodiation at C-termini, 
glutamic and aspartic acid side chains, c) Swiss Protein database (20051115), Homo sapiens 
taxonomy, d) 0.15Da mass accuracy for precursor peptides and e) 0.3Da mass accuracy for 
peptide fragment ion mass measurement. The resulting search yielded the likelihood of 
peptide homology or identity by a given total ion MOWSE (Molecular Weight Search) 
score. Given the above stipulations, peptides with a total ion score ≥ 20 provide for 
assignment of the peptide amino acid sequence with absolute identification or with near 
absolute homology. To confirm peptide assignments for the four candidate peptides, 
synthetic peptides were purchased and MALDI-TOF/TOF spectra acquired and compared to 
experimental spectra.
Immunoblot Analysis for Plasma Protein Abundance
In order to examine if the increased plasma abundance of kininogen fragments was the result 
of increased kininogen protein expression and abundance of protein degradation products, 
immunoblot experiments using reduced and denatured plasma protein samples were 
conducted as described previously23. In brief, plasma proteins were isolated following 
albumin depletion. Albumin was removed from 200 μg aliquots with the VivaPure anti-HSA 
kit for human albumin depletion (Vivascience, Sartorius Group). Albumin depleted plasma 
samples were concentrated to dryness with a vacuum concentrator (Thermo Savant SC210A 
Speedvac concentrator), re-dissolved in 100 μl 10mM Tris HCl, pH 7.8 and protein assayed. 
Samples (10 μg) were mixed with NuPAGE LDS Sample Buffer (Invitrogen, Inc.) and DTT, 
then heated to 70C for 10 min. Samples were applied to NuPAGE 4-12% Bis-Tris gels 
(Invitrogen, Inc.) and electrophoresed for 40 minutes at 200V. The proteins were transferred 
to 0.45 μm nitrocellulose membrane, 90 min at 30V using NuPAGE transfer buffer 
(Invitrogen, Inc.) with 20% methanol. After transfer, membranes were blocked with 
Odyssey™ Blocking buffer (LiCor Biosciences, Inc.) for 1 hr and incubated with Goat anti-
Kininogen antibody (R&D Systems cat# AF1569) (1:500 in Odyssey™ blocking buffer/
0.1%Tween 20) at 4C. Membranes were washed with TTBS (Tris-buffered saline/0.1% 
Tween 20). Following 1 hour incubation with IRdye800-conjugated Donkey anti-Goat 
(1:5000 in Odyssey™/Tween) membranes were scanned using the Odyssey™ infrared 
imaging system (LiCorBioSciences, Inc.).
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glucose and des-Arg9 BK (1-8)
An immortalized C57 black mouse proximal tubule cell line (compliments of Jeffery 
Schelling, MD, Case Western Reserve University) were cultured in T-25 flasks at 33 C in 
DMEM:F-12 (1:1) medium supplemented with 10% heat inactivated FBS to 60% 
confluence. The cells were then serum starved overnight at 33 C in normal glucose, low 
serum medium (0.5% serum) and then exchanged into low serum treatment medium (5mM 
glucose, NG; 5mM glucose + 25mM mannitol, M; 30mM glucose, HG) plus 0.5% serum. 
After 24h at 33 C the cells were treated for 10 min with agonist vehicle (PBS) or agonist 
(des-Arg9 BK) followed by collecting lysates using RIPA buffer. Total lysate (5 mg) was 
loaded under reducing/denaturing conditions, separated using gradient PAGE gels and 
immunoblotted as previously described onto 0.45um nitrocellulose.24,25 The blotted 
membrane was blocked in 1% milk overnight, probed with primary antibody at 1:1000 
(sc-7383, Santa Cruz Biotechnology, Inc, Santa Cruz, CA), secondary antibody at 1:5000 
(sc-93, Santa Cruz Biotechnology, Inc, Santa Cruz, CA), and bands imaged using luminol 
and film. The phospho-Erk2 densitometry was normalized to total-Erk1/2 and then 
normalized to the mannitol-PBS control experiment. Differences in immunoblot 
densitometry were determined by an analysis of variance (ANOVA) of immunoblot 
experiment data and Newman-Kuels post hoc analysis of treatment pairs by t-test.
To determine the effects of polarization on Erk1/2 phosphorylation, immortalized C57 black 
mouse proximal tubule cell line were seeded onto permeable inserts in 6-well at 
approximately 10-20 percent density, grown at 33 C in DMEM:F-12 (1:1) medium 
supplemented with 10% heat inactivated FBS to 70-80% confluence. The cells were then 
serum starved overnight at 33 C in normal glucose, low serum medium (0.5% serum) and 
then exchanged into low serum treatment medium (5mM glucose, NG; 5mM glucose + 
25mM mannitol, M; 30mM glucose, HG) plus 0.5% serum. After 24h at 33 C the cells were 
treated apical or basilar administration of the vehicle or peptide for 10 min followed by 
collecting lysates using RIPA buffer.
To determine the effects of cell type on Erk1/2 phosphorylation by glucose and apical 
peptide delivery, an opossum kidney proximal tubule cell line (OKC) were seeded onto 
permeable inserts in 6-well at approximately 10-20 percent density, grown at 37 C in 
DMEM medium supplemented with 10% heat inactivated FBS to 70-80% confluence. The 
cells were then serum starved overnight at 37 C in normal glucose, low serum medium 
(0.5% serum) and then exchanged into low serum treatment medium (5mM glucose, NG; 
5mM glucose + 25mM mannitol, M; 30mM glucose, HG) plus 0.5% serum. After 24h at 37 
C the cells were treated apical administration of the vehicle or peptide for 10 min followed 
by collecting lysates using RIPA buffer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Graphical illustration for the abundances of plasma peptides that correlate with future 
severe progressive renal function decline demonstrating increased abundance in decliner (case) 
over non-decliner (control) plasma samples
Aligned MS data sets were constructed from peptide mass and retention time, and estimated 
peptide abundance was calculated from the MS ion cluster signal area or inferred from 
baseline when peptides were not detected.
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tFigure 2. High molecular weight kininogen is increased in plasma of patients with future renal 
dysfunction
The plasma samples of cases (n=6) and controls (n=6) were depleted of albumin, divided 
between two 10% gels, separated and transferred onto nitrocellulose membranes and probed 
with mono-specific antibodies to high molecular weight kininogen (one of two blots shown, 
Panel 2a). Pooled data for all samples were analyzed by densitometry and are shown in 
Panel 2b). Statistical differences were estimated using a Student’s t-test.
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tFigure 3. Induction of extracellular-signal-regulated kinases (ERK1/2) phosphorylation by 
glucose and des-Arg9-BK (1-8) (DABK) in proximal tubule cell lines
Proximal tubule cell lines were used to determine the effects of 10 minute des-Arg9- BK 
treatment on Erk1/2 phosphorylation. Cells were seeded onto permeable inserts, grown to 
70% confluence, serum starved and then cultured in medium containing 0.5% FBS plus 
normal glucose (5mM glucose, NG), osmotic control (5mM glucose + 25mM mannitol, M) 
or high glucose (30mM glucose, HG). After 24h the cells were treated for 10 min with 
agonist vehicle (PBS) or agonist (DABK). A C57 mouse proximal tubular cell line 
(compliments of Jeffery Schelling, MD, Case Western Reserve University) was used to 
ascertain peptide effects as a function of apical (A) or basilar (B) treatment. An opossum 
kidney (OK) cell line was used to confirm apical delivery (C) findings of C57 cell line 
experiment. Cell lysates from treated cells were immunoblotted for phospho-Erk1/2 (p-
Erk1/2) then stripped and re-probed for Erk-2. The percentage of Erk-2 phosphorylation 
induced by culture or treatment was estimated from band densitometry ratios for (p-Erk-2 
band of p-Erk 1/2 IB densitometry) to (Erk-2). Statistical differences indicated in plots are 
estimated by ANOVA analysis (Kruskal-Wallis) with Dunn’s post hoc comparison of 
means. Data are plotted as mean and standard error of the mean.
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Table 1
Characterization of plasma peptides whose abundance strongly correlates with the rate of 
future renal function decline.
The integrated area under the curve for plasma peptide data was extracted from aligned LC-MALDI-TOF MS 
data sets and analyzed by Spearman correlation analysis to the estimated rate of renal function decline 
(estimated using serum concentration of cystatin C and changes in renal function were estimated by slopes). 
Peptides with strong correlation (between −0.45 and −1.0) to progressive renal function decline are listed. The 
difference in the observed abundance of plasma peptides selected by the Spearman correlation was estimated 
using unpaired t-test with Welch’s correction for unequal variation in case and control peptide abundance data 
sets.
Peptide
Mass (m/z)
Spearman’s Rank
Correlation
Coefficient (rs)
P-value*
For comparison
of cases and
controls
Mascot
MOWSE
Score**
Peptide or protein fragment
Identified
757.402 −0.51 0.006 36 des-Phe8-des-Arg9-Bradykinin (1-7)
(K)-RPPGFSP-(F)
904.472 −0.46 0.03 44 des-Arg9-Bradykinin (1-8)
(K)-RPPGFSPF-(R)
920.467 −0.45 0.06 44 Hyp3-des-Arg9-Bradykinin (1-8)
(K)-RP-Hyp-GFSPF-(R)
1675.794 −0.50 0.03 96 Kallikrein sensitive glycoprotein (ITIH4)
(P)-GPPDVPDHAAYHPFR-(R)
Unidentified
789.394 −0.48 0.01 na
945.453 −0.46 0.01 na
1050.099 −0.46 0.02 na
*
Analysis by T-test (with Welch’s correction for unequal variances) of differences in abundance of peptides in case (n= 16) and control (n= 17) 
samples.
**
Mascot MOWSE scores ≥ 20 are considered significant (p-value < 0.05) and provide for identity.
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